Since entering the oncology space in 2006, Glenmark has remained committed to transforming cancer care for patients across India. Cancer diagnoses are life-altering, and we aim to provide patients with the best possible treatments to manage their conditions and improve their quality of life. From chemotherapy-induced nausea and vomiting to advanced therapies targeting specific cancers, our portfolio offers hope to thousands of cancer patients every year.

Our journey began with the launch of Aprepitant, a breakthrough treatment that revolutionized the management of chemotherapy-induced nausea and vomiting. This drug became a cornerstone of our oncology portfolio, helping patients complete their chemotherapy cycles with fewer disruptions. Since then, we have expanded our offerings to include therapies for Prostate Cancer, Breast Cancer, Lung Cancer, and hematological malignancies.

Recently, we launched new therapies for advanced prostate cancer, ovarian cancer, and breast cancer associated with genetic mutations, addressing critical gaps in cancer care. Approximately 12,000 patients have benefited from these treatments, which focus on improving survival rates and reducing side effects. Our latest medicine for chemotherapy-induced nausea received the prestigious New Drug of the Year award in India, a testament to our innovation and patient-centered approach in oncology.